Truist Financial Cuts IQVIA (NYSE:IQV) Price Target to $216.00

IQVIA (NYSE:IQV) had its price objective decreased by Truist Financial from $263.00 to $216.00 in a research note released on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the medical research company’s stock.

Several other research firms also recently commented on IQV. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Mizuho cut their price target on IQVIA from $242.00 to $210.00 and set an “outperform” rating on the stock in a research report on Wednesday. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Finally, Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Price Performance

NYSE IQV opened at $145.40 on Thursday. The company has a market cap of $25.64 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock’s fifty day moving average price is $182.32 and its 200 day moving average price is $199.64. IQVIA has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

Large investors have recently modified their holdings of the business. Independence Bank of Kentucky grew its position in shares of IQVIA by 42.9% in the first quarter. Independence Bank of Kentucky now owns 580 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 174 shares in the last quarter. Nixon Peabody Trust Co. grew its holdings in IQVIA by 11.7% in the 1st quarter. Nixon Peabody Trust Co. now owns 63,823 shares of the medical research company’s stock valued at $11,252,000 after buying an additional 6,684 shares in the last quarter. Sendero Wealth Management LLC increased its stake in shares of IQVIA by 16.1% in the 1st quarter. Sendero Wealth Management LLC now owns 52,486 shares of the medical research company’s stock worth $9,253,000 after acquiring an additional 7,265 shares during the last quarter. Whipplewood Advisors LLC raised its holdings in shares of IQVIA by 7,142.2% during the 1st quarter. Whipplewood Advisors LLC now owns 3,259 shares of the medical research company’s stock worth $575,000 after acquiring an additional 3,214 shares during the period. Finally, ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.